EC Number | Activating Compound | Comment | Organism | Structure |
---|---|---|---|---|
3.4.21.77 | 17-allylamine-17-demethoxygeldanamycin | - |
Homo sapiens | |
3.4.21.77 | AUY922 | reduces PSA concentration in a dose-dependent manner (2fold more than insulin-like growth factor-binding protein 2) and is accompanied by androgen receptor decrease | Homo sapiens | |
3.4.21.77 | dihydrotestosterone | hormonal treatment of BT-474 cells with dihydrotestosterone (an androgen) for 48 h triggers an increase of prostate-specific antigen concentration in the supernatant of these cells | Homo sapiens | |
3.4.21.77 | insulin-like growth factor-binding protein 2 | - |
Homo sapiens | |
3.4.21.77 | norgestrel | hormonal treatment of BT-474 cells with norgestrel (an androgenic progestin) for 48 h triggers an increase of prostate-specific antigen concentration in the supernatant of these cells | Homo sapiens |
EC Number | Application | Comment | Organism |
---|---|---|---|
3.4.21.77 | medicine | PSA may serve as a sensitive biomarker of Hsp90 inhibition and may aid in selecting new chemotherapeutics | Homo sapiens |
EC Number | Inhibitors | Comment | Organism | Structure |
---|---|---|---|---|
3.4.21.77 | AUY922 | - |
Homo sapiens |
EC Number | Organism | UniProt | Comment | Textmining |
---|---|---|---|---|
3.4.21.77 | Homo sapiens | - |
- |
- |
EC Number | Source Tissue | Comment | Organism | Textmining |
---|---|---|---|---|
3.4.21.77 | BT-474 cell | minute amounts | Homo sapiens | - |
3.4.21.77 | LNCaP cell | - |
Homo sapiens | - |
3.4.21.77 | serum | - |
Homo sapiens | - |
EC Number | Synonyms | Comment | Organism |
---|---|---|---|
3.4.21.77 | KLK3 | - |
Homo sapiens |
3.4.21.77 | prostate-specific antigen | - |
Homo sapiens |
3.4.21.77 | PSA | - |
Homo sapiens |
EC Number | IC50 Value | IC50 Value Maximum | Comment | Organism | Inhibitor | Structure |
---|---|---|---|---|---|---|
3.4.21.77 | 0.000001 | - |
- |
Homo sapiens | AUY922 |
EC Number | Organism | Comment | Expression |
---|---|---|---|
3.4.21.77 | Homo sapiens | at a dose of 0.00001 mM 17-allylamine-17-demethoxygeldanamycin, PSA expression is reduced by 40%. 17-allylamine-17-demethoxygeldanamycin-treated LNCaP cells reveal about 25% inhibition of PSA secretion. Potency of AUY922 to reduce PSA expression at inhibitor concentrations lower than 0.000005 mM (non-toxic at these levels) is greater (8fold) than the potency of 17-allylamine-17-demethoxygeldanamycin. Hsp90 inhibitors target PSA secretion via the androgen receptor pathway | down |